Home / Research library / Enclomiphene
Enclomiphene: molecular data, studies & sources
Enclomiphene is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C26H28ClNO
- Molecular weight (MW)
- 406.0 g/mol
- PubChem compound ID
- 1548953
- Record title
- Enclomiphene
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 1548953 · retrieved 2026-09-21
Chemical identifiers and source data
- IUPAC name
- 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine
- InChIKey
- GKIRPKYJQBWNGO-OCEACIFDSA-N
- SMILES
- CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3
Identifiers
- PubChem CID
- 1548953
- CAS Registry Number
- 15690-57-0via ChemIDplus, EPA DSSTox, FDA GSRS
- FDA UNII
- R6D2UI4FLS
- ChEMBL ID
- CHEMBL954
- InChIKey
- GKIRPKYJQBWNGO-OCEACIFDSA-N
- Wikidata
- Q28208734
Other names and development codes: Enclomifene · ICI-46476 · RMI 16,289
CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-07.
Calculated molecular descriptors
| Monoisotopic (exact) mass | 405.1859 Da |
|---|---|
| Heavy atoms | 29 |
| Hydrogen-bond donors | 0 |
| Hydrogen-bond acceptors | 2 |
| Rotatable bonds | 9 |
| Topological polar surface area | 12.5 Ų |
| Calculated logP (Crippen) | 6.56 |
| Rings | 3 |
| Stereocenters | 0 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
US regulatory status & drug development
Drug development record (ChEMBL)
Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.
- ChEMBL ID
- CHEMBL954
- Modality
- Small molecule
- Highest clinical stage
- Phase 3
- Record name
- ENCLOMIPHENE
Mechanism of action
- Estrogen receptor alpha modulator · target: Estrogen receptor (ESR1)
Synonyms, codes and trade names
- Synonyms and development codes
- Enclomifene · Enclomiphene · ICI-46476 · ISOMER B · ISOMER-B · RMI 16,289 · RMI-16289
Identity check: Identical standard InChIKey to the PubChem record. Source: ChEMBL CHEMBL954 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-07
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Enclomiphene as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
22 registered studies matched, 9 with results posted on ClinicalTrials.gov.
- By highest phase
- Phase 3 · 9Phase 2 · 4Phase 1 · 9
- By registry status
- Completed · 22
Show 12 more registered studies
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal FunctionNCT01923857 · start 2013-08 · primary completion 2014-08 | Phase 1Completed | Secondary Hypogonadism | Repros Therapeutics Inc.26 participants |
| Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic FunctionNCT01923870 · start 2013-08 · primary completion 2014-01 | Phase 1Completed | Secondary Hypogonadism | Repros Therapeutics Inc.19 participants |
| An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary HypogonadismNCT01739582 · start 2012-11 · primary completion 2014-04 | Phase 3Completed | Secondary Hypogonadism | Repros Therapeutics Inc.300 participants |
| Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary HypogonadismNCT01739595 · start 2012-11 · primary completion 2013-09 | Phase 3CompletedResults posted 2015-05-27 | Secondary Hypogonadism | Repros Therapeutics Inc.181 participants |
| Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary HypogonadismNCT01619683 · start 2012-09 · primary completion 2014-09 | Phase 3Completed | Effect of Treatment on Bone Mineral Density | Repros Therapeutics Inc.300 participants |
| Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary HypogonadismNCT01532414 · start 2012-08 · primary completion 2013-03 | Phase 3CompletedResults posted 2015-05-27 | Secondary Hypogonadism | Repros Therapeutics Inc.151 participants |
| Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary HypogonadismNCT01534208 · start 2012-05 · primary completion 2013-10 | Phase 3CompletedResults posted 2014-07-24 | Secondary Hypogonadism | Repros Therapeutics Inc.499 participants |
| The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)NCT01386606 · start 2011-06 · primary completion 2011-10 | Phase 2CompletedResults posted 2015-09-23 | Secondary Hypogonadism | Repros Therapeutics Inc.60 participants |
| Normalization of Morning Testosterone Levels in Men With Secondary HypogonadismNCT01270841 · start 2011-01 · primary completion 2011-12 | Phase 2CompletedResults posted 2014-07-28 | Secondary Hypogonadism | Repros Therapeutics Inc.83 participants |
| To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical TestosteroneNCT00706719 · start 2008-06 · primary completion 2009-07 | Phase 2CompletedResults posted 2010-10-08 | Secondary Hypogonadism | Repros Therapeutics Inc.17 participants |
| Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary HypogonadismNCT00962637 · start 2006-03 · primary completion 2007-05 | Phase 3Completed | Secondary Hypogonadism | Repros Therapeutics Inc.194 participants |
| Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary HypogonadismNCT01067365 · start 2006-03 · primary completion 2007-05 | Phase 3Completed | Secondary Hypogonadism | Repros Therapeutics Inc.104 participants |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Enclomiphene, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human study · PubMed trial index Compound given to participants
Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement.
Kim ED, McCullough A, Kaminetsky J et al. · BJU international · 2016
PMID 26496621 · DOI: 10.1111/bju.13337
- Human study · PubMed trial index Compound given to participants
Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel.
Kaminetsky J, Werner M, Fontenot G et al. · The journal of sexual medicine · 2013
PMID 23530575 · DOI: 10.1111/jsm.12116
- Human study · PubMed trial index Compound given to participants
Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone.
Wiehle RD, Fontenot GK, Wike J et al. · Fertility and sterility · 2014
PMID 25044085 · DOI: 10.1016/j.fertnstert.2014.06.004 · Registration NCT01270841
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Research publication · design requires review
Safety and efficacy of enclomiphene and clomiphene for hypogonadal men.
Saffati G, Kassab J, Orozco Rendon D et al. · Translational andrology and urology · 2024
PMID 39434750 · DOI: 10.21037/tau-24-238
- Review · secondary evidence
Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men.
Hill S, Arutchelvam V, Quinton R et al. · IDrugs : the investigational drugs journal · 2009
PMID 19204885
Enclomiphene supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Enclomiphene for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Nova Peptide SupplyUSD | 12.5mg×60 Capsules · 12.5mg-per-mL-30mL Solution2 recorded offers | 12.5mg×60 Capsules · $99.99Checked Nov 6, 2026Supplier listing, Enclomiphene 12.5mg×60 Capsules, Nova Peptide Supply, opens in a new tab |
| Cenexa LabsUSD | 12.5mg×60 Capsules1 recorded offers | 12.5mg×60 Capsules · $79.99Recorded out of stock · Checked Nov 6, 2026Supplier listing, Enclomiphene 12.5mg×60 Capsules, Cenexa Labs, opens in a new tab |
| Amino USAUSD | 12.5mg-per-mL-30mL Solution1 recorded offers | 12.5mg-per-mL-30mL Solution · $55.00Checked Nov 6, 2026Supplier listing, Enclomiphene 12.5mg-per-mL-30mL Solution, Amino USA, opens in a new tab |
Reference sources & further reading
- PubChem compound record 1548953 — chemical identity and structure.
- ChEMBL drug record CHEMBL954 — development stage, mechanism and synonyms.
- FDA Global Substance Registration System: UNII R6D2UI4FLS — substance identity, names and codes.
- Wikipedia: Enclomifene — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
ACE-031
Molecular identity needs further verification
3 selected publications · 2 human intervention studies · 4 registered trials
Adipotide
C111H206N36O28S2
2557.2 g/mol · PubChem CID 163360068
1 selected publication · 0 human intervention studies
AICAR
C9H14N4O5
258.23 g/mol · PubChem CID 17513
4 selected publications · 3 human intervention studies · 4 registered trials
Small molecule · highest stage: Phase 3
B7-33
Molecular identity needs further verification
4 selected publications · 0 human intervention studies
BAM15 Capsules
Molecular identity needs further verification
8 selected publications · 0 human intervention studies
Dermorphin
C40H50N8O10
802.9 g/mol · PubChem CID 5485199
1 selected publication · 1 human intervention study